NO167662B - 4-substituted-2-azetidinone. - Google Patents
4-substituted-2-azetidinone. Download PDFInfo
- Publication number
- NO167662B NO167662B NO870289A NO870289A NO167662B NO 167662 B NO167662 B NO 167662B NO 870289 A NO870289 A NO 870289A NO 870289 A NO870289 A NO 870289A NO 167662 B NO167662 B NO 167662B
- Authority
- NO
- Norway
- Prior art keywords
- azetidinone
- group
- substituted
- general formula
- mmol
- Prior art date
Links
- -1 4-substituted-2-azetidinone Chemical class 0.000 title claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical group O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- GKMYZUXPHIFASZ-BYPYZUCNSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-4-oxoazetidine-2-carboxylate Chemical compound O=C([C@H]1NC(=O)C1)ON1C(=O)CCC1=O GKMYZUXPHIFASZ-BYPYZUCNSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BXRMEWOQUXOLDH-LURJTMIESA-N L-Histidine methyl ester Chemical group COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- AXIQMEOYYYWDKF-LBPRGKRZSA-N benzyl (2s)-2-amino-3-(1h-imidazol-5-yl)propanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CNC=N1 AXIQMEOYYYWDKF-LBPRGKRZSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000010701 ester synthesis reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 150000003953 γ-lactams Chemical class 0.000 description 1
Description
Foreliggende oppfinnelse angår nye 4-substituerte 2-azetidinonforbindelser av generell formel VII The present invention relates to new 4-substituted 2-azetidinone compounds of general formula VII
hvori R g betegner et hydrogenatom, en laverealkylgruppe eller en aralkylgruppe, eller et salt derav. wherein R g denotes a hydrogen atom, a lower alkyl group or an aralkyl group, or a salt thereof.
Eksempler på den laverealkylgruppe vist ved R i den foregående generelle formel VII er rettkjedede eller forgre-nede alkylgrupper med 1 til 5, fortrinnsvis 1 til 3 carbon-atomer slik som en methylgruppe, en ethylgruppe, en propyl-gruppe, en butylgruppe, en pentylgruppe, en isopropylgruppe etc, og eksempler på aralkylgruppene vist ved R oer aryl-laverealkylgrupper slik som en benzylgruppe, en fenethylgruppe, en nafthylmethylgruppe etc. Examples of the lower alkyl group shown by R in the preceding general formula VII are straight-chain or branched alkyl groups with 1 to 5, preferably 1 to 3 carbon atoms such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group , an isopropyl group, etc., and examples of the aralkyl groups shown by R are aryl-lower alkyl groups such as a benzyl group, a phenethyl group, a naphthylmethyl group, etc.
De nye forbindelser vist ved generell formel VII er anvendbare som mellomprodukter for fremstilling av terapeutisk aktive forbindelser vist ved generell formel I som beskrevet i norsk patent 158 740. The new compounds shown by general formula VII are usable as intermediates for the production of therapeutically active compounds shown by general formula I as described in Norwegian patent 158 740.
Forbindelsen vist ved generell formel VII kan fremstilles ved omsetning av en carboxylsyre vist ved formel The compound shown by general formula VII can be prepared by reacting a carboxylic acid shown by formula
eller et reaktivt derivat derav, og et amin av generell formel hvori R o har den ovenfor angitte betydning, eller et reaktivt derivat derav. Reaksjonen er en peptidsyntesereaksjon og kan utføres på kjent måte. Ennvidere angår oppfinnelsen nye 4-substituerte 2-azetidinonforbindelser av generell formel 9 hvori R betegner or a reactive derivative thereof, and an amine of general formula in which R o has the above meaning, or a reactive derivative thereof. The reaction is a peptide synthesis reaction and can be carried out in a known manner. Furthermore, the invention relates to new 4-substituted 2-azetidinone compounds of general formula 9 in which R denotes
og fremgangsmåte for fremstilling av disse. and method for producing these.
Den foregående forbindelse er anvendbar som et mellomprodukt for fremstilling av forbindelsene av formel VII, dg er ennvidere anvendbar som mellomprodukt for fremstilling av g-lactamserier av antibiotika. The preceding compound is usable as an intermediate for the preparation of the compounds of formula VII, dg is also usable as an intermediate for the preparation of γ-lactam series of antibiotics.
Det nye mellomproduktet fremstilles ved omsetning av en carboxylsyre av formel The new intermediate is produced by reacting a carboxylic acid of formula
eller et reaktivt derivat derav og pentaklorfenol eller N-hydroxysuccinimid. or a reactive derivative thereof and pentachlorophenol or N-hydroxysuccinimide.
Reaksjonen er en estersyntesereaksjon og en kjent The reaction is an ester synthesis reaction and a known one
forestringsmetode kan hensiktsmessig velges. esterification method can be suitably chosen.
Oppfinnelsen illustreres ytterligere ved de etter-følgende eksempler. The invention is further illustrated by the following examples.
De forkortelser som anvendes i eksemplene har føl-gende betydning: The abbreviations used in the examples have the following meaning:
TLC Tynnskiktskromatografi TLC Thin layer chromatography
NMR Kjernemagnetisk resonansspektrum NMR Nuclear magnetic resonance spectrum
IR Infrarød absorpsjonsspektrum Masse' Masseanalysespektrum IR Infrared absorption spectrum Mass' Mass analysis spectrum
Z Benzyloxycarbonyl Z Benzyloxycarbonyl
Bn Benzyl Bn Benzyl
His Histidin His Histidine
Pro Prolin Pro Proline
DNP 2,4-dinitrofenyl DNP 2,4-dinitrophenyl
Ts Tosyl TS Tosyl
BOC t-butyloxycarbonyl BOC t-butyloxycarbonyl
DMF Dimethylformamid DMF Dimethylformamide
HOBT N-hydroxy-1,2,3-benzotriazol HOBT N-hydroxy-1,2,3-benzotriazole
DCC Dicyclohexylcarbodiimid DCC Dicyclohexylcarbodiimide
THF tetrahydrofuran THF tetrahydrofuran
HOSu N-hydroxysuccinimid HOSu N-Hydroxysuccinimide
Ph Fenyl Ph Phenyl
Eksempel 1 Example 1
I 200 ml DMF ble oppløst 10 g (8,68 mmol) (S)-2-azetidinon-4-carboxylsyre (2) og 24,4 g (8,68 mmol) pentaklorfenol hvoretter 17,93 g (8,70 mmol) DCC ble tilsatt til løs-ningen under avkjøling (0 til 5°C).. Etter omrøring av blandingen i 5 timer ved romtemperatur ble det utfelte dicyclo-hexylurea filtrert fra og filtratet ble konsentrert under redusert trykk. Det dannede residuum ble oppløst i 200 ml ethylacetat ved oppvarmning og ble deretter avkjølt. De utfelte krystaller ble oppsamlet ved filtrering under dannelse av 25,6 g gulaktige krystaller av (S)-4-pentaklorfenoxycarbonyl-2-azetidinon (58) med et smeltepunkt på 177 til 179°C. 10 g (8.68 mmol) of (S)-2-azetidinone-4-carboxylic acid (2) and 24.4 g (8.68 mmol) of pentachlorophenol were dissolved in 200 ml of DMF, after which 17.93 g (8.70 mmol ) DCC was added to the solution under cooling (0 to 5°C).. After stirring the mixture for 5 hours at room temperature, the precipitated dicyclohexylurea was filtered off and the filtrate was concentrated under reduced pressure. The residue formed was dissolved in 200 ml of ethyl acetate by heating and was then cooled. The precipitated crystals were collected by filtration to give 25.6 g of yellowish crystals of (S)-4-pentachlorophenoxycarbonyl-2-azetidinone (58) with a melting point of 177 to 179°C.
NMR (90 MHz, d<6->DMSO-D20) <6>ppm: 3,23 (1.H, q, azetidinonring 3-stilling), 3,57 (1H, q, azetidinonring 3-stilling), 4,70 (1H, q, azetidinonring 4-stilling) NMR (90 MHz, d<6->DMSO-D2O) <6>ppm: 3.23 (1.H, q, azetidinone ring 3-position), 3.57 (1H, q, azetidinone ring 3-position), 4 .70 (1H, q, azetidinone ring 4-position)
IR (KBr) cm"<1>: 3200, 1775, 1755, 1720 IR (KBr) cm"<1>: 3200, 1775, 1755, 1720
Masse: 363 (M<+>), 335, 266, 237 Mass: 363 (M<+>), 335, 266, 237
Eksempel 2 Example 2
I 20 ml DMF ble oppløst 690 mg (S)-2-azetidinon-4-carboxylsyre (2) og etter tilsetning av 690 mg HOSu og 1,236 g DCC under isavkjøling fikk reaksjonen forløpe i 30 minutter under isavkjøling og deretter i 4 timer ved romtemperatur. Uløselige bestanddeler ble filtrert fra reaksjonsblandingen hvoretter løsningsmidlet ble destillert fra under dannelse av et lysebrunt, fast materiale. Produktet ble omkrystallisert fra dioxan-petroleumether (5:1) under dannelse av 7 50 mg (S)-4-(2,5-dioxopyrrolidin-1-yl)-oxycarbonyl-2-azetidinon. 690 mg of (S)-2-azetidinone-4-carboxylic acid (2) was dissolved in 20 ml of DMF and after adding 690 mg of HOSu and 1.236 g of DCC under ice cooling, the reaction was allowed to proceed for 30 minutes under ice cooling and then for 4 hours at room temperature . Insolubles were filtered from the reaction mixture after which the solvent was distilled off to give a light brown solid. The product was recrystallized from dioxane-petroleum ether (5:1) to give 750 mg of (S)-4-(2,5-dioxopyrrolidin-1-yl)-oxycarbonyl-2-azetidinone.
NMR (DMSO-d<6>, TMS) Sppm: 8,70 (bred, 1H), 4,62 (dd, 1H), NMR (DMSO-d<6>, TMS) Spppm: 8.70 (broad, 1H), 4.62 (dd, 1H),
3,84 (s, 4H) 3.84 (s, 4H)
IR (KBr) cm<-1>: 3320, 2920, 2840, 1810, 1780, 1750, 1730, IR (KBr) cm<-1>: 3320, 2920, 2840, 1810, 1780, 1750, 1730,
1720, 1650, 1620, 1570 1720, 1650, 1620, 1570
Masse (CI i stråle): 213 (M+ + 1), 185, 171, 116 Mass (CI in beam): 213 (M+ + 1), 185, 171, 116
Eksempel 3 Example 3
I 75 ml DMF ble suspendert 6,05 g (25 mmol) L-histi-dinmethylester-2-hydroklorid (59) og etter avkjøling av suspensjonen til 0 til 5°C ble 5,05 g (50 mmol) triethylamin langsomt, dråpevis tilsatt til suspensjonen. Deretter ble blandingen omrørt i 15 minutter ved samme temperatur. In 75 ml DMF was suspended 6.05 g (25 mmol) L-histidine methyl ester-2-hydrochloride (59) and after cooling the suspension to 0 to 5°C 5.05 g (50 mmol) triethylamine was added slowly, dropwise added to the suspension. The mixture was then stirred for 15 minutes at the same temperature.
9,50 g (25 mmol) av forbindelse (58) ble tilsatt til blandingen som et pulver, og etter omrøring av blandingen i 9.50 g (25 mmol) of compound (58) was added to the mixture as a powder, and after stirring the mixture in
én time ved samme temperatur fikk blandingen stå over natten ved romtemperatur. Triethylaminhydroklorid ble filtrert fra, filtratet ble konsentrert under redusert trykk. Residuet ble blandet med 4 0 ml ethylacetat og 30 ml vann etterfulgt av risting, hvoretter det vandige lag ble oppsamlet. Ethylace-tatlaget ble ekstrahert to ganger med 20 ml vann. Det vandige lag ble kombinert og vannet ble destillert fra under redusert trykk. Residuet ble blandet med acetonitril og benzen og blandingen ble konsentrert under redusert trykk. Residuet ble krystallisert fra 30 ml methanol og krystallene ble opp- one hour at the same temperature, the mixture was allowed to stand overnight at room temperature. Triethylamine hydrochloride was filtered off, the filtrate was concentrated under reduced pressure. The residue was mixed with 40 ml of ethyl acetate and 30 ml of water followed by shaking, after which the aqueous layer was collected. The ethylacetate layer was extracted twice with 20 ml of water. The aqueous layers were combined and the water was distilled off under reduced pressure. The residue was mixed with acetonitrile and benzene and the mixture was concentrated under reduced pressure. The residue was crystallized from 30 ml of methanol and the crystals were
samlet under dannelse av 4,1 g av f arveløse krystaller av N<01->collected to give 4.1 g of f heirless crystals of N<O1->
[(S)-2-a2etidinon-4-carbonyl]-L-histidinmethylester (60) med smeltepunkt på 142 til 14 7°c. [(S)-2-α2etidinone-4-carbonyl]-L-histidine methyl ester (60) mp 142 to 147°C.
NMR (90 MHz, d<6->DMSO) 6ppm: 2,94 (2H, d, 6-stilling methylen av histidingruppe), 3,60 (3H, s, methylgruppe), 4,02 (1H, q, azetidinonring 4-stilling), 4,54 (1H, m, a-stilling methin av histidingruppe), 6,72 (1H, s, imidazolring), 7,56 (1H, s, imidazolring), 8,20 (Hf, s, NH) , 8,56 (1H, d, azetidinonring NH) NMR (90 MHz, d<6->DMSO) 6ppm: 2.94 (2H, d, 6-position methylene of histidine group), 3.60 (3H, s, methyl group), 4.02 (1H, q, azetidinone ring 4-position), 4.54 (1H, m, a-position methine of histidine group), 6.72 (1H, s, imidazole ring), 7.56 (1H, s, imidazole ring), 8.20 (Hf, s , NH) , 8.56 (1H, d, azetidinone ring NH)
IR (KBr) cm"<1>: 3250, 3100, 2950, 1770, 1750, 1740, 1720, IR (KBr) cm"<1>: 3250, 3100, 2950, 1770, 1750, 1740, 1720,
1650, 1550 1650, 1550
Eksempel 4 Example 4
I 20 ml kloroform ble oppløst 1,178 g (2 mmol) histidinbenzylester.2-p-toluensulfonat hvoretter 404 mg (2 mmol) triethylamin ble langsomt tilsatt til løsningen under isavkjøling til 0°C. Til løsningen ble tilsatt 766 mg (2 mmol) (S)-4-pentaklorfenoxycarbonyl-2-azetidinon (58) som et pulver og blandingen ble omrørt over natten ved 0 til 5°C. 1.178 g (2 mmol) of histidine benzyl ester, 2-p-toluenesulfonate were dissolved in 20 ml of chloroform, after which 404 mg (2 mmol) of triethylamine was slowly added to the solution under ice-cooling to 0°C. To the solution was added 766 mg (2 mmol) of (S)-4-pentachlorophenoxycarbonyl-2-azetidinone (58) as a powder and the mixture was stirred overnight at 0 to 5°C.
Til reaksjonsblandingen ble tilsatt 30 ml kloroform og det ønskede produkt ble ekstrahert to ganger, hver gang med 3 0 ml vann. Deretter ble vannet destillert fra under redusert trykk og det dannede residuum ble azeotropisk dehydrert med benzen-acetonitril under dannelse av et farveløst, klebrig produkt. Produktet ble underkastet silicagelkolonnekromatografi under anvendelse av 50 ml Wako-gel C-200 og eluert med ethylacetat-methanol-konsentrert, vandig ammoniakk (60:30:3) under dannelse av 470 mg N et- [(S)-2-azetidinon-4-carbonyl]-L-histidinbenzyl-ester (60-1) med smeltepunkt på 196 til 199°C som farveløse krystaller. To the reaction mixture was added 30 ml of chloroform and the desired product was extracted twice, each time with 30 ml of water. Then the water was distilled off under reduced pressure and the resulting residue was azeotropically dehydrated with benzene-acetonitrile to form a colorless sticky product. The product was subjected to silica gel column chromatography using 50 ml of Wako gel C-200 and eluted with ethyl acetate-methanol-concentrated aqueous ammonia (60:30:3) to give 470 mg of N et-[(S)-2-azetidinone- 4-carbonyl]-L-histidine benzyl ester (60-1) mp 196 to 199°C as colorless crystals.
NMR (90 MHz, d<6->DMSO) 6ppm: 2/58 MH' m' azetidinonring 3-stilling), 2,96 (2H, d, histidingruppe 6-stilling methylen), 3,12 (1H, m, azetidinonring 3-stilling), 4,00 (1H, m, azetidinonring 4-stilling), 4,62 (1H, NMR (90 MHz, d<6->DMSO) 6ppm: 2/58 MH' m' azetidinone ring 3-position), 2.96 (2H, d, histidine group 6-position methylene), 3.12 (1H, m, azetidinone ring 3-position), 4.00 (1H, m, azetidinone ring 4-position), 4.62 (1H,
m, histidingruppe a-stilling methin), 5,10 (2H, s, benzylstilling), 6,80 (1H, s, imidazolring), 7,36 (5H, s, benzenring), 7,56 (1H, s, imidazolring), 8,20 (1H, s, NH), 8,58 (1H, d, NH) m, histidine group a-position methine), 5.10 (2H, s, benzyl position), 6.80 (1H, s, imidazole ring), 7.36 (5H, s, benzene ring), 7.56 (1H, s, imidazole ring), 8.20 (1H, s, NH), 8.58 (1H, d, NH)
IR (KBr) cm"<1>: 3260, 2980, 2760, 1750, 1650, 1540 IR (KBr) cm"<1>: 3260, 2980, 2760, 1750, 1650, 1540
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO870289A NO167662C (en) | 1983-03-25 | 1987-01-23 | 4-substituted-2-azetidinone. |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58048989A JPS59225182A (en) | 1983-03-25 | 1983-03-25 | Derivative of 2-azetidinone-4-carboxylic acid |
JP58221470A JPS60115578A (en) | 1983-11-25 | 1983-11-25 | 2-azetidinone-4-substituted compound |
JP58221469A JPS60115577A (en) | 1983-11-25 | 1983-11-25 | 2-azetidinone-4-substitution product |
NO841158A NO158740C (en) | 1983-03-25 | 1984-03-23 | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE 4-SUBSTITUTED 2-AZETIDINONE COMPOUNDS. |
NO870289A NO167662C (en) | 1983-03-25 | 1987-01-23 | 4-substituted-2-azetidinone. |
Publications (3)
Publication Number | Publication Date |
---|---|
NO870289L NO870289L (en) | 1984-09-26 |
NO167662B true NO167662B (en) | 1991-08-19 |
NO167662C NO167662C (en) | 1991-11-27 |
Family
ID=27522766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO870289A NO167662C (en) | 1983-03-25 | 1987-01-23 | 4-substituted-2-azetidinone. |
Country Status (1)
Country | Link |
---|---|
NO (1) | NO167662C (en) |
-
1987
- 1987-01-23 NO NO870289A patent/NO167662C/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO167662C (en) | 1991-11-27 |
NO870289L (en) | 1984-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0354583B1 (en) | DC-88A derivatives | |
NO329020B1 (en) | difluoropyridine | |
US6048864A (en) | Quinolines and quinazolines useful in therapy | |
US4987232A (en) | Preparation of 2-chloropyridine 3-carboxylic acid esters | |
US4684662A (en) | Disubstituted proline derivatives | |
SU888815A3 (en) | Method of preparing nitrocompound | |
GB2213146A (en) | Pyrimidine derivatives | |
KR20210151056A (en) | Method for preparing DON prodrug from L-pyroglutamic acid | |
US4032559A (en) | N,2-dicyanoacetimidates | |
US4703051A (en) | 4,7-dihydrothieno[2,3-B]pyridine derivatives useful in the treatment of cardiovascular diseases | |
US5856495A (en) | Process for the preparation of triazolinone herbicides | |
HU182636B (en) | Process for producing pyrazolo-imidazol derivatives | |
US5968967A (en) | Pyrazolones derivatives | |
US4734508A (en) | Process and intermediates for preparing 4-substituted proline derivatives | |
NO167662B (en) | 4-substituted-2-azetidinone. | |
FI66853B (en) | MELLAN PRODUCTS FOR ANALYZING THE HYPOTENSIVE 2- (4- (2-FUROYL) PIPERAZIN-1-YL) -6,7-DIMETOXYQUINAZOLINE | |
US5112855A (en) | Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds and compositions | |
CA2149007C (en) | Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseases | |
MXPA02000316A (en) | Benzofurane derivatives. | |
US5126455A (en) | Preparation of substituted alkali metal piperidine-4-carboxylates | |
Takiguchi et al. | Antifungal Activities of α-Isocyano-β-phenylpropionamides | |
EP0132964A2 (en) | 2-Azabicyclo[2.2.2]octane derivatives | |
EP0602458A1 (en) | 1,4-Benzoxazine derivatives | |
Selby et al. | Synthesis and structure elucidation of 3‐methoxy‐1‐methyl‐1H‐1, 2, 4,‐triazol‐5‐amine and 5‐methoxy‐1‐methyl‐1H‐1, 2, 4,‐triazol‐3‐amine | |
JP3459270B2 (en) | Preparation of N-tert-butoxycarbonyl-maleimide |